IPP Bureau
Aurigene introduces AI/ML assisted drug discovery platform
By IPP Bureau - April 04, 2024
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Evonik unveils latest global trial results MetAMINO
By IPP Bureau - April 04, 2024
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Max CMD Abhay Soi is new president of NATHEALTH
By IPP Bureau - April 04, 2024
New leadership team announced at NATHEALTH Annual General Meeting 2024
Colgate Active Salt redefines oral hygiene with a new and improved formula
By IPP Bureau - April 03, 2024
EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
By IPP Bureau - April 03, 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names
By IPP Bureau - April 02, 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities
By IPP Bureau - April 02, 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director
By IPP Bureau - April 02, 2024
Apotex to acquire Canadian Searchlight Pharma
By IPP Bureau - April 02, 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Vivity reaches 1 million milestone
By IPP Bureau - April 02, 2024
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Viatris launches RYZUMVl 0.75% in US
By IPP Bureau - April 02, 2024
The average time of dilation lasts three to eight hours
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
By IPP Bureau - April 02, 2024
Application based on results from the TROPION-Breast01 Phase III trial
MTD acquires Ypsomed's pen needle and BGM businesses
By IPP Bureau - April 01, 2024
This acquisition enables MTD to open new, strategic markets
Bio-Techne partners with Nikon Instruments for innovative spatial biology services
By IPP Bureau - April 01, 2024
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
